Author

Ian Mersich

Cincinnati Children's Hospital Medical CenterORCID 0000-0002-1679-404XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Abby GrieriD· 1 shared Aktar AliiD· 1 shared Ali TavassoliiD· 1 shared Angelo D’AlessandroiD· 1 shared Biplab DasguptaiD· 1 shared Brian S. J. BlaggiD· 1 shared Cailing Yin· 1 shared Charles B. StevensoniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abby GrierORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integrated Genomic Profiling Reveals Mechanisms of Broad Drug Resistance and Opportunities for Phenotypic Reprogramming in Cancer Cells

Ian Mersich, Brian S. J. Blagg, Aktar Ali

This study identifies mechanisms of broad drug resistance in cancer and proposes strategies to reverse it using integrated genomic and computational approaches.

bioRxiv · Sep 4, 2025 · PreprintCancer Biology

Integrative Multi-Omics Analysis Identifies Nuclear Factor I as a Key Driver of Dysregulated Purine Metabolism in DIPG

Ian Mersich, Sunny Congrove, Matthew J. Horchar, Román Cáceres, Ranjithmenon Muraleedharan, Janki M. Desai, Pankaj B. Desai, Larry Sallans, Julie A. Reisz, Abby Grier, Matthew R. Hass, Omer Donmez, Cailing Yin, Matthew T. Weirauch, Leah Claire Kottyan, , Biplab Dasgupta

This study identifies nuclear factor I (NFI) as a driver of dysregulated purine metabolism in DIPG, showing that targeting ATIC reduces tumor progression in mice.

bioRxiv · May 21, 2025 · PreprintCancer Biology